TICKERNERD
Menu
RLAYRLAYHealthcare · Biotechnology

RLAY Stock Forecast: Relay Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 17 Aug 2026
$21
+4.08% on the day

The 14 Wall Street analysts covering Relay Therapeutics, Inc. hold a median 12-month price target of $26 — +25.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 75 of 100 as at 17 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$4.4B
Ticker Nerd rank
75 / 100
Median analyst target
$26
Analysts covering
14
Total return, dividends reinvested
1W
+3.7%
1M
+3.8%
YTD
+144.3%
1Y
+483.9%
From 52W high
−0.4%
From 52W low
+507.9%
$3
$21
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

RLAY stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Relay Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Aug 2026
75 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
100
Value
85
Quality
74
Accruals
69
Growth
65
Revisions
47
Volatility
47
Issuance
41
Size
26

Momentum (100): The shares have been drifting up relative to others.

Issuance (41): The company has been issuing shares or taking on financing, diluting existing holders.

Size (26): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

RLAY stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RLAY, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20$25$30$35Oct 25Jan 26Apr 26Jul 26RLAYHigh $32Median $26Low $20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says14 analysts
14 Buy0 Hold0 Sell
Low $20Median $26High $32

The green dot is the last close — the median target sits +25.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
14 Aug 2026JP MorganMaintainsOverweight$28 → $31
10 Aug 2026CitizensMaintainsMarket Outperform$21 → $26
7 Aug 2026BarclaysMaintainsOverweight$27 → $30
21 July 2026Goldman SachsMaintainsBuy$22 → $31
21 July 2026Goldman SachsMaintainsBuy—
16 July 2026Canaccord GenuityInitiatesBuy$29
16 July 2026Canaccord GenuityInitiatesBuy—
8 July 2026JP MorganInitiatesOverweight—
26 May 2026GuggenheimMaintainsBuy—
26 May 2026HC Wainwright & Co.MaintainsBuy—
20 May 2026BarclaysMaintainsOverweight—
20 May 2026CitizensMaintainsMarket Outperform—
19 May 2026Raymond JamesMaintainsStrong Buy—
29 Apr 2026HC Wainwright & Co.MaintainsBuy—
28 Apr 2026CitizensMaintainsMarket Outperform—
28 Apr 2026Goldman SachsMaintainsBuy—
28 Apr 2026OppenheimerMaintainsOutperform—
28 Apr 2026Wells FargoMaintainsOverweight—
14 Apr 2026Jones TradingInitiatesHold—
8 Apr 2026BarclaysMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RLAY appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

RLAY analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Relay Therapeutics, Inc. (RLAY) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−12.3×

Cheaper than 94% of US stocks

Price / sales
420.5×

Cheaper than 2% of US stocks

Price / book
4.9×

Cheaper than 22% of US stocks

EV / EBITDA
−11.3×

Cheaper than 85% of US stocks

Growth & margins
Revenue growth (YoY)
−48.3%

Higher than 6% of US stocks

Earnings growth (YoY)
−48.3%

Higher than 10% of US stocks

Gross margin
—
Operating margin
−25949.7%

Higher than 1% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−36.8%

Higher than 25% of US stocks

Return on assets
−22.9%

Higher than 17% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

RLAY vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
RLAYRelay Therapeutics, Inc.$4.4B
75
MANEVeradermics, Inc.$4.5B
2
PBLSParabilis Medicines, Inc.$4.4B
0
CELCCelcuity, Inc.$4.5B
29
ELVNEnliven Therapeutics, Inc.$4.3B
68
EWTXEdgewise Therapeutics, Inc.$4.7B
50
TNGXTango Therapeutics, Inc.$4.1B
44

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Relay Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RLAY news & analysis

4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma

Zacks Investment Research · 17 Aug 2026neutral

Zacks highlighted RLAY among four companies using AI-powered platforms to transform drug discovery while advancing proprietary clinical pipelines. The article presents RLAY as one of several AI-powered drug discovery stocks to watch as AI reshapes pharma.

Why it matters — RLAY watchers would care because the company is being recognized for leveraging AI in its drug discovery approach while also advancing its own clinical pipeline.

Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue Estimates

Zacks Investment Research · 7 Aug 2026neutral

Relay Therapeutics reported a quarterly loss of $0.41 per share for Q2, in line with the Zacks Consensus Estimate and unchanged from the $0.41 per share loss a year earlier, while its revenue fell short of estimates.

Why it matters — A RLAY watcher would care because the results show earnings met expectations but revenue lagged amid the company's ongoing losses.

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

GlobeNewsWire · 6 Aug 2026positive

Relay Therapeutics reported second-quarter 2026 financial results and corporate updates. The company selected z ovegalisib plus atirmociclib as its go-forward triplet regimen for first-line breast cancer, with a Phase 3 trial in endocrine-sensitive patients expected to initiate in early 2027, subject to regulatory feedback.

Why it matters — The selection of a go-forward triplet regimen and the expected Phase 3 trial initiation mark a key next step for Relay's breast cancer program.

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

GlobeNewsWire · 30 July 2026neutral

Relay Therapeutics announced it will report its second quarter 2026 financial results and corporate highlights after U.S. markets close on August 6, 2026. The news was shared via a press release on July 30, 2026.

Why it matters — RLAY watchers will look to the August 6 report for updates on the company's clinical programs, financial position, and corporate progress.

Relay Therapeutics, Inc. (RLAY) Expected to Beat Earnings Estimates: Should You Buy?

Zacks Investment Research · 30 July 2026positive

Zacks Investment Research reported that Relay Therapeutics (RLAY) has the right combination of key ingredients likely to result in an earnings beat in its upcoming report.

Why it matters — A potential earnings beat could influence investor sentiment around the company's near-term financial performance.

FAQ

Frequently asked questions about RLAY stock

What is the RLAY stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Relay Therapeutics, Inc. have a median 12-month price target of $26, with estimates ranging from $20 to $32. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RLAY stock a buy right now?

Of the 14 analysts covering Relay Therapeutics, Inc., 14 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Relay Therapeutics, Inc. 75 out of 100 across roughly 4,600 US stocks as at 17 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RLAY?

As at 17 Aug 2026, Relay Therapeutics, Inc. ranks 75 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (100 of 100).

Will RLAY stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +25.8% from the last close, and Ticker Nerd's factor model ranks Relay Therapeutics, Inc. 75 out of 100 as at 17 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RLAY stock forecast for 2030?

No analyst covering Relay Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RLAY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $32 over the next 12 months.

How has RLAY stock performed over the past year?

Relay Therapeutics, Inc. returned +483.9% over the 12 months to 17 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Relay Therapeutics, Inc. do?

Relay Therapeutics Inc. is a clinical-stage precision medicine company focused on transforming drug discovery through its proprietary Dynamo platform, which integrates computational modeling, machine learning, and experimental approaches to target dynamic protein motions for small molecule therapeutics.

What is the latest news on RLAY?

The most recent item we track (Zacks Investment Research, 17 Aug 2026): "4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma". Zacks highlighted RLAY among four companies using AI-powered platforms to transform drug discovery while advancing proprietary clinical pipelines. The article presents RLAY as one of several AI-powered drug discovery stocks to watch as AI reshapes pharma.

Company

About Relay Therapeutics, Inc.

Relay Therapeutics Inc. is a clinical-stage precision medicine company focused on transforming drug discovery through its proprietary Dynamo platform, which integrates computational modeling, machine learning, and experimental approaches to target dynamic protein motions for small molecule therapeutics. The company specializes in oncology and genetic diseases, with its lead candidate RLY-2608 (zovegalisib), a pan-mutant and isoform-selective PI3Kα inhibitor in clinical development for PI3Kα-mutated HR+/HER2- metastatic breast cancer, solid tumors, and vascular malformations, often in combination with fulvestrant or CDK4/6 inhibitors. Additional programs include an αGal chaperone for Fabry disease, RLY-8161 targeting NRAS-driven tumors, and RLY-1013 as an estrogen receptor alpha degrader. Relay Therapeutics Inc. maintains collaborations with partners like D. E. Shaw Research for computational target analysis, Elevar Therapeutics for lirafugratinib (RLY-4008) in FGFR2-driven cancers, and Pfizer for combination therapies. Founded in 2015 and headquartered in Cambridge, Massachusetts, it plays a key role in advancing precision oncology by addressing challenging protein targets to develop potentially transformative treatments.

CEO Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS · 202 employees · United States · https://www.relaytx.com